Abstract 1431P
Background
Neoadjuvant chemotherapy combined with immunotherapy (nCIT) is emerging as a promising strategy for treating patients with esophageal cancer. We aimed to develop a novel, voxel-level radiomics deep learning model to predict the pathological complete response (pCR) to nCIT in esophageal squamous cell carcinoma (ESCC).
Methods
We included 745 ESCC patients from three institutions, comprising a training set (N=500, institution 1), test-set-1 (N=86, institution 1), test-set-2 (N=34, institution 2), and test-set-3 (N=125, institution 3). All patients underwent nCIT and received a pathological evaluation post-surgery. A total of 104 distinct radiomic features were extracted from the tumor areas in CT images prior to nCIT. Features demonstrating predictive power with an area under the receiver operating characteristic curve (AUROC) exceeding 0.6 were retained. Each selected radiomics feature map, along with the original image, was input into a vision transformer model as a separate channel. The Shapley Additive exPlanations method was employed to visualize feature importance and identify predictive regions within the tumor, enhancing the model’s interpretability. For baseline comparison, we also constructed a clinical model using only clinical factors, and compared it against traditional radiomics and ResNet models.
Results
The voxel-level radiomics deep learning model achieved an AUC of 0.825 with an accuracy of 76.2% in test-set-1, 0.751 and 68.5% in test-set-2, and 0.819 with 78.1% in test-set-3, respectively. It demonstrated superior predictive performance compared to the clinical model, traditional radiomics model, and ResNet model.
Conclusions
This innovative and noninvasive voxel-level radiomics deep learning approach offers an efficient and accurate approach of predicting treatment response to nCIT in ESCC, potentially benefiting clinical decision-making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. Zhang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
961P - Sodium-glucose co-transporter 2 inhibitors (SGLT2i) improve oncologic outcomes in diabetic patients with hepatocellular carcinoma (HCC): A nationwide database study
Presenter: Chien-Huai Chuang
Session: Poster session 17
962P - Best practices and impact of multi-disciplinary teams on hepatocellular carcinoma treatment: Insights from a global effort
Presenter: Pablo Azcue
Session: Poster session 17
963P - Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab + rivoceranib (cam+rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310
Presenter: Andrew Moon
Session: Poster session 17
964P - Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR)
Presenter: Markus Peck Radosavljevic
Session: Poster session 17
967P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster session 17
968P - HAIC combined with lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors for advanced HCC with portal vein tumor thrombosis: A prospective controlled trial
Presenter: Xiaodong Wang
Session: Poster session 17
969P - Lenvatinib versus sorafenib as a second-line option in patients with unresectable hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab: An observational study
Presenter: Pasquale Lombardi
Session: Poster session 17
970P - Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma: A single-center, real-world study
Presenter: Yangxun Pan
Session: Poster session 17
Resources:
Abstract
971P - Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative optionfor advanced unresectable intrahepatic cholangiocarcinoma: A retrospective real-world study
Presenter: binghua dai
Session: Poster session 17